Statin: Scoping Review with ☸️SAIMSARA.

Name: SAIMSARA Evidence Object vascular::STATIN_SS
Creator: SAIMSARA
License: https://saimsara.com/license/

Cardiac & Vascular Health

Issue 1, Volume 1, 2026

Chat with this issue

DOI: 10.62487/f5760313

Editorial note

• Last update: 2026-03-27 12:21:06

What is this paper about

This paper shows that statins remain one of the strongest cardiovascular therapies, consistently linked to fewer major events and lower mortality across very large populations, but not without trade-offs such as diabetes risk, muscle symptoms, and rises in lipoprotein(a). The full paper is worth reading because it shows where the benefit is most convincing, where the risks matter most, and how to think more clearly about the real balance between protection and harm.

Abstract: This paper aims to comprehensively synthesize the current evidence on the multifaceted effects of statin therapy, encompassing both its benefits and risks across various physiological systems and patient populations, to identify key clinical implications and future research directions. The review utilises 4734 original studies with 141,699,669 total participants (topic deduplicated ΣN). Across this evidence map, statin therapy most consistently aligns with improved cardiovascular outcomes in high-risk settings, including signals supporting reduced major adverse cardiovascular events and mortality, while also highlighting recurrent safety trade-offs such as higher risk of incident type 2 diabetes and increases in lipoprotein(a). Beyond lipid lowering, the mapped literature repeatedly points to pleiotropic pathways—anti-inflammatory and plaque-stabilizing effects—appearing across domains such as heart failure, stroke, and infectious/critical illness outcomes. At the same time, associations with musculoskeletal symptoms and other system-specific adverse outcomes underscore the need for individualized risk–benefit discussions and monitoring, particularly in susceptible subgroups. Interpretation is limited by the scoping design and the LLM-assisted classification workflow, which prioritize breadth over causal certainty and may introduce misclassification. Clinically, the map supports early and sustained statin use where cardiovascular risk is high while motivating research to better stratify diabetes risk and to clarify the clinical significance of statin-associated lipoprotein(a) increases.

Keywords: Statins; Type 2 diabetes mellitus; Atrial fibrillation; Heart failure; Dementia; Chronic kidney disease; Adverse drug reactions; Lipoprotein; Acute myocardial infarction; Sepsis-associated acute kidney injury

Review Stats

Final search date and database lock: 2026-03-10 14:32:56 CET
Plan: Pro (expanded craft tokens; source: PubMed)
Source: PubMed
Total Abstracts/Papers: 32271
Downloaded Abstracts/Papers: 8950
Included original and non-original Abstracts/Papers (all): 5577
Included original Abstracts/Papers (Vote counting by direction of effect): 4734
Reference Index (links used in paper): 369
Total participants (topic deduplicated ΣN): 141699669

Get access to the full paper

Unlock the full evidence map

Full paper access includes the complete human-readable review, figures, reference index, PDF export, and machine-readable Evidence JSON download.
Evidence JSON can also be purchased separately if you only need the LLM-ready object for agent, AI, or RAG workflows.
Institutional or library access? Sign in with your institution email to open all available SAIMSARA papers under your institution access arrangement.
Need a SAIMSARA review on your own topic? ☸️Request.

Reference Index (369)

[1] Statin therapy increases lipoprotein(a) levels. — https://doi.org/10.1093/eurheartj/ehz310
[2] Worsening of myasthenic symptoms associated with statins. — https://doi.org/10.1016/j.jns.2024.123154
[3] Statin Use and the Progression of Coronary Artery Calcification in CKD: Findings From the KNOW-CKD Study. — https://doi.org/10.1016/j.ekir.2024.07.033
[4] Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention. — https://doi.org/10.1186/s12933-024-02498-3
[5] Statin-induced risk of diabetes does not reduce cardiovascular benefits in primary prevention: a 6-year propensity-score matched study in a large population. — https://doi.org/10.1186/s12933-025-02798-2
[6] The impact of early use of statin in sepsis patients with acute kidney injury: a study based on MIMIC-IV. — https://doi.org/10.3389/fphar.2025.1610450
[7] Statin Use Among Women and Men Following Coronary Artery Bypass Surgery. — https://doi.org/10.1161/jaha.124.039011
[8] High-intensity statin on 3-year clinical outcomes in elderly acute myocardial infarction patients underwent percutaneous coronary intervention with drug-eluting stents. — https://doi.org/10.1038/s41598-025-19385-w

Unlock the full paper to view the complete Reference Index.